Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Checkpoint Blockade Immunotherapy Combined With SBRT in Advanced Metastatic Disease
NCT02843165Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Sep 2016
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic cancer (2 arms), sponsored by University of California, San Diego. Primary endpoint: Objective Response Rate at 16 weeks. Started Sep 2016; status: completed.
02
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT02843165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843165.